

Contact:

Kathryn Morris

KMorrisPR

845-635-9828

**Vitae Pharmaceuticals Announces Promotion of Tina Fiumenero to
Chief Financial Officer**

Fort Washington, Pennsylvania – October 23, 2008 –Vitae Pharmaceuticals, Inc., an emerging pharmaceutical company dedicated to the discovery and development of innovative small molecule medicines, announced today that it has promoted Tina Fiumenero to the position of Chief Financial Officer.

“Tina’s intense focus on building shareholder value and driving capital efficiency have helped put Vitae in a strong financial position,” said Jeffrey Hatfield, Chief Executive Officer of Vitae. “As Vitae continues to advance its growing pipeline, Tina’s impressive strategic and operational skills will help ensure Vitae’s long-term ability to succeed.”

Ms. Fiumenero joined Vitae in January 2006 as Senior Vice President, Finance and Administration. Prior to joining Vitae Pharmaceuticals, Ms. Fiumenero spent 13 years at Bristol-Myers Squibb where she held a number of finance positions of increasing responsibility spanning U.S. commercial operations, mergers and acquisitions and manufacturing. Prior to joining Bristol-Myers Squibb, Ms. Fiumenero worked as a financial auditor for Coopers & Lybrand. She holds a B.S. degree in accounting from New York University and is a Certified Public Accountant.

Vitae Pharmaceuticals is an emerging pharmaceutical company with a unique and powerful structure-based drug design engine and a rapidly maturing portfolio of high value discovery programs. Vitae’s goal is to discover, develop and commercialize innovative new medicines, alone and in partnership, that will be best-in-class in important therapeutic areas such as cardiovascular and metabolic disease,

inflammation and CNS. Vitae Pharmaceuticals is financed by leading corporate and venture capital investors and is headquartered in Fort Washington, Pennsylvania. For additional information, please visit the company's website, www.vitaepharma.com.

###